Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo‐Controlled Clinical Trial

Kranzler, Henry R., Wesson, Donald R., Billot, Laurent, DrugAbuse Sciences Naltrexone Depot Study Group·2004·Alcoholism: Clinical and Experimental Research

Abstract

Background: Studies of the efficacy of naltrexone for alcohol dependence have yielded variable findings, which may be due, in part, to variation in compliance with oral naltrexone. Efforts to improve naltrexone compliance have included the development of injectable, long‐acting depot formulations. Methods: We conducted a multicenter trial in 315 subjects who were randomly assigned to receive an intramuscular injection of a depot formulation containing naltrexone (n= 158) or a placebo formulation (n= 157) monthly for 3 months. All patients received five sessions of manual‐guided motivational enhancement therapy during the 12 weeks of the study. The outcomes of interest were based on self‐reported alcohol use and γ‐glutamyl transpeptidase level. Missing data or data from subjects who discontinued the study were conservatively treated as heavy‐drinking days. Results: Groups were comparable on pretreatment demographic and clinical measures. The medication was well tolerated; 73.7% of subjects received all injections. The time to the first heavy‐drinking day, the percentage of subjects with no heavy drinking throughout the study, and γ‐glutamyl transpeptidase levels favored the naltrexone depot, although the effects did not reach statistical significance. There was a significant advantage for naltrexone depot treatment on the time to the first drinking day. Naltrexone depot subjects also had significantly fewer drinking days during treatment and a significantly greater abstinence rate than the placebo group (18% vs. 10%). Conclusions: This is the first multicenter study of a depot formulation of naltrexone for the treatment of alcohol dependence. Using a conservative intent‐to‐treat analysis, the study showed an advantage for the active medication. Further research with this formulation is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.alc.0000130804.08397.29

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 169

Metadata

Authors
Kranzler, H. R., Wesson, D. R., Billot, L., & DrugAbuse Sciences Naltrexone Depot Study Group
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2004-07
Volume
28
Issue
7
Pages
1051-1059
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2118229177
Cited by
169
References
6
FWCI
11.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo‐Controlled Clinical Trial. https://app.cochat.ai/papers/10.1097/01.alc.0000130804.08397.29
The paper
Kranzler, H. R., Wesson, D. R., Billot, L., & DrugAbuse Sciences Naltrexone Depot Study Group. (2004). Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo‐Controlled Clinical Trial. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1097/01.alc.0000130804.08397.29

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.